BRIEF published on 03/14/2025 at 17:50, 30 days 12 hours ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
BRIEF published on 03/14/2025 at 17:50, 30 days 12 hours ago PHAXIAM Therapeutics cherche repreneur en redressement judiciaire Euronext Paris Redressement Judiciaire PHAXIAM Therapeutics Recherche Repreneur Prolongation Procédure
PRESS RELEASE published on 03/14/2025 at 17:45, 30 days 12 hours ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
PRESS RELEASE published on 03/14/2025 at 17:45, 30 days 12 hours ago Informations privilégiées / Autres communiqués PHAXIAM Therapeutics lance un processus de recherche de repreneurs dans le cadre de son redressement judiciaire. Appel d'offres ouvert jusqu'au 11 avril 2025 Appel D'offres Redressement Judiciaire Repreneurs Procédure PHAXIAM Therapeutics
BRIEF published on 03/06/2025 at 18:01, 1 month 7 days ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
BRIEF published on 03/06/2025 at 18:01, 1 month 7 days ago PHAXIAM Therapeutics entre en redressement judiciaire et retarde ses résultats financiers Retard Des Résultats Financiers Administrateur Judiciaire Suspension Des Échanges Mise Sous Séquestre De PHAXIAM Défis Biotechnologiques
PRESS RELEASE published on 03/06/2025 at 17:56, 1 month 7 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
PRESS RELEASE published on 03/06/2025 at 17:56, 1 month 7 days ago Informations privilégiées / Autres communiqués PHAXIAM annonce l'ouverture d'une procédure de redressement judiciaire et le report de la publication de ses résultats financiers 2024. La Société se place sous la protection du Tribunal de commerce de Lyon Résultats Financiers Tribunal De Commerce Redressement Judiciaire PHAXIAM Procédure
BRIEF published on 03/06/2025 at 11:45, 1 month 7 days ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 03/06/2025 at 11:45, 1 month 7 days ago Suspension de la Cotation de PHAXIAM Therapeutics Euronext Paris Biopharmaceutique Suspension Cotation PHAXIAM Therapeutics Infections Résistantes
Published on 04/12/2025 at 15:45, 1 day 14 hours ago New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 2 days 3 hours ago Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 2 days 5 hours ago Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/11/2025 at 23:45, 2 days 6 hours ago Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties
Published on 04/11/2025 at 21:45, 2 days 8 hours ago OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:38, 2 days 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/11/2025 at 18:23, 2 days 11 hours ago EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:30, 2 days 11 hours ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:30, 2 days 11 hours ago Reclassement d'actions au sein du concert familial Feuillet sans incidence sur le contrôle de la société
Published on 04/11/2025 at 18:00, 2 days 11 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2025
Published on 04/11/2025 at 18:00, 2 days 11 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:50, 2 days 12 hours ago Mise à disposition du Rapport Financier Annuel 2024
